THE DEAL, AT A GLANCE
From the announcementVaderis Therapeutics
01What it doesVaderis is a science-driven, patient-focused biotech with a singular aim: to be the first to bring breakthrough therapies to people with HHT and other rare vascular…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by StealthFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedVaderis Therapeutics raised $152M Series B, announced 2026-08-11From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersVaderis Therapeutics is financing clinical development in HHT and other rare vascular diseases through an oversubscribed Series B tied to initiation of the global Phase…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Vaderis Therapeutics · Financing Record
Explore source-linked visual explanations for Vaderis Therapeutics. Unsupported claims are withheld while source review continues.
Record 10040 · Recorded date: 2026-08-11
Explore company records →